Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
uniQure N.V. QURE
$21.91
-$0.24 (-1.11%)
На 18:00, 12 мая 2023
+144.96%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1048404735.00000000
-
week52high
28.26
-
week52low
12.52
-
Revenue
106483000
-
P/E TTM
-8
-
Beta
1.16989600
-
EPS
-2.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Equal-Weight | 09 авг 2022 г. |
| Chardan Capital | Buy | Buy | 09 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 мая 2022 г. |
| Credit Suisse | Outperform | Outperform | 03 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 02 сент 2022 г. |
| Goldman Sachs | Buy | Buy | 03 ноя 2022 г. |
| Goldman Sachs | Buy | Buy | 23 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Soteropoulos Paula | D | 2000 | 6000 | 18 янв 2023 г. |
| Soteropoulos Paula | D | 16382 | 6000 | 18 янв 2023 г. |
| Soteropoulos Paula | A | 22382 | 6000 | 18 янв 2023 г. |
| Soteropoulos Paula | D | 0 | 3800 | 14 дек 2022 г. |
| Soteropoulos Paula | D | 16382 | 3800 | 14 дек 2022 г. |
| Soteropoulos Paula | A | 20182 | 3800 | 14 дек 2022 г. |
| Soteropoulos Paula | D | 8000 | 3000 | 13 дек 2022 г. |
| Soteropoulos Paula | D | 16382 | 3000 | 13 дек 2022 г. |
| Soteropoulos Paula | A | 19382 | 3000 | 13 дек 2022 г. |
| Dolmetsch Ricardo | D | 127406 | 2219 | 09 дек 2022 г. |
Новостная лента
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 09:56
UniQure (QURE) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1 per share a year ago.
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
27 февр 2023 г. в 09:47
uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
uniQure: An FDA Approval, An Advancing Pipeline And A Critical Data Readout
Seeking Alpha
18 февр 2023 г. в 08:46
Hemgenix was approved by FDA. uniQure appears undervalued based on the value of milestones and royalties due to the company.
uniQure: Hemgenix Approval Key Catalyst To Move The Needle, Rate Buy
Seeking Alpha
07 дек 2022 г. в 06:35
Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49.
uniQure: FDA Approval Achieved, Along With AMT-130 Moving Forward
Seeking Alpha
06 дек 2022 г. в 15:05
FDA approval of uniQure N.V.'s Hemgenix for the treatment of adults with Hemophilia B achieved. There is potential to receive European approval of Hemgenix for the treatment of adults with Hemophilia B in 2023 on standard review timeline.